A 4-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic, and Exploratory Efficacy of Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension
Latest Information Update: 18 Jul 2024
At a glance
- Drugs Venglustat (Primary) ; Imiglucerase
- Indications Gaucher's disease type I; Gaucher's disease type III
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Acronyms LEAP
- Sponsors Sanofi Genzyme
- 12 Sep 2023 Planned number of patients changed from 15 to 18.
- 12 Sep 2023 Planned number of patients changed from 15 to 18.
- 13 Feb 2023 Results published in the Brain